Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven M Grunberg

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 27, 2002
Antiemetic guidelines: creating a more practical treatment approachJim M Koeller, Matti S Aapro, Richard J Gralla, et al.
Cancer|May 13, 2004
Incidence of chemotherapy-induced nausea and emesis after modern antiemeticsSteven M Grunberg, Robert R Deuson, Panagiotis Mavros, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|February 16, 2013
Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kineticsMichael J Toth, Mark S Miller, Damien M Callahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapyJørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2014
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapyDorothy M Keefe, Linda S Elting, Hoang T Nguyen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsDavid G Warr, Steven M Grunberg, Richard J Gralla, et al.
Cancer|April 25, 2003
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomitingSant P Chawla, Steven M Grunberg, Richard J Gralla, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lungKelly J Butnor, Mary Beth Beasley, Philip T Cagle, et al.
Cancer|August 17, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt, Hyman B Muss, David G Warr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2006
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, Mark G Kris, Paul J Hesketh, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|September 27, 2002
Antiemetic guidelines: creating a more practical treatment approachJim M Koeller, Matti S Aapro, Richard J Gralla, et al.
Cancer|May 13, 2004
Incidence of chemotherapy-induced nausea and emesis after modern antiemeticsSteven M Grunberg, Robert R Deuson, Panagiotis Mavros, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|February 16, 2013
Molecular mechanisms underlying skeletal muscle weakness in human cancer: reduced myosin-actin cross-bridge formation and kineticsMichael J Toth, Mark S Miller, Damien M Callahan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2009
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapyJørn Herrstedt, Wichit Apornwirat, Ahmed Shaharyar, et al.
Cancer Chemotherapy and Pharmacology|July 25, 2014
Risk and outcomes of chemotherapy-induced diarrhea (CID) among patients with colorectal cancer receiving multi-cycle chemotherapyDorothy M Keefe, Linda S Elting, Hoang T Nguyen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 9, 2005
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trialsDavid G Warr, Steven M Grunberg, Richard J Gralla, et al.
Cancer|April 25, 2003
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomitingSant P Chawla, Steven M Grunberg, Richard J Gralla, et al.
Archives of Pathology & Laboratory Medicine|October 2, 2009
Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lungKelly J Butnor, Mary Beth Beasley, Philip T Cagle, et al.
Cancer|August 17, 2005
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapyJørn Herrstedt, Hyman B Muss, David G Warr, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2006
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006, Mark G Kris, Paul J Hesketh, et al.
Pageof 5